Healthcare, Pharma & Life Sciences

Apex Dental Partners Lands Eighth Straight Inc. 5000 Ranking

Dallas – September 24, 2026 -- Apex Dental Partners has been named No. 3,850 on the Inc. 5000 list of America's fastest-growing private companies, marking its eighth consecutive year on the ranking after posting 67% revenue growth over the past three years.

Apex secures its eighth straight Inc. 5000 placement on sustained revenue growth

The Dallas-based dental partnership organization, which supports dentists and affiliated practices, achieved the 67% three-year revenue growth figure that placed it at No. 3,850 on the annual list published by Inc. magazine. The Inc. 5000 ranks privately held U.S. companies strictly by percentage revenue growth over a three-year period, making Apex's eight consecutive appearances a marker of consistent expansion in the fragmented dental services sector.

Genzeon Wins UiPath 2026 Healthcare Industry Impact Partner Award

Image
Genzeon Wins UiPath 2026 Healthcare Industry Impact Partner Award

Las Vegas – September 24, 2026 -- Genzeon has been named UiPath's 2026 Industry Impact Partner of the Year for Healthcare and Life Sciences, recognizing five years of joint automation work that has processed hundreds of thousands of healthcare transactions annually.

The award was presented at UiPath FUSION 2026 and cited Genzeon's role in converting AI and robotic process automation into measurable financial and operational outcomes for payers, providers and life sciences clients.

Prior authorization platform handles 450,000 cases annually under CMS mandate

For the CMS WISeR program, Genzeon and UiPath built prior authorization infrastructure processing more than 450,000 cases per year across 17 high-risk service categories. The system automates 85% to 90% of routine determinations while meeting mandatory 72-hour turnaround windows and complying with FHIR and CMS-0057-F requirements.

LaserAway Opens 232nd Clinic in Lubbock, Marks 20 Years, Zero Closures

Image
LaserAway Opens 232nd Clinic in Lubbock, Marks 20 Years, Zero Closures

Los Angeles – – September 24, 2026 -- LaserAway has opened its 232nd U.S. clinic in Lubbock, Texas, extending a 20-year run without a single location closure since its 2006 founding.

Lubbock clinic expands LaserAway's footprint to 36 states

The new site at 4210 82nd St, #206, Lubbock, TX 79423, will offer laser hair removal, Botox, dermal fillers, skin rejuvenation, and body contouring treatments including CoolSculpting and Thermage. It will also add LaserAway Wellness Injections administered by licensed medical staff.

Company scales from one West Hollywood clinic to 232 locations

LaserAway was founded in 2006 by Dr. Roy Winston and brothers Scott, Brock, and Todd Heckmann, starting with a single clinic on Sunset Boulevard in West Hollywood, CA. The company remains privately owned and operated, with no franchised locations, and now operates across 36 states.

Drones Deliver Freeze-Dried Plasma to Ukraine's Front-Line Wounded

Image
Drones Deliver Freeze-Dried Plasma to Ukraine's Front-Line Wounded

Aurora, Colo. – September 24, 2026 -- Researchers at the University of Colorado Anschutz report a 100% 24-hour survival rate among 26 Ukrainian military personnel who received drone-delivered freeze-dried plasma at the point of injury, a preliminary finding from an ongoing study testing whether unmanned aircraft can bring blood products to critically injured patients before conventional evacuation reaches them.

Drones carry Octapharma-donated plasma to front-line medics in Ukraine

The freeze-dried plasma, donated by global pharmaceutical company Octapharma, is packaged for transport and flown by drone to medical teams operating near the point of injury. Unlike fresh frozen plasma, which requires freezing and thawing, the freeze-dried version can be stored at room temperature and prepared rapidly for administration, addressing a logistical barrier the FDA has identified for battlefield, remote and disaster settings.

Oracle Launches AI-Powered Oncology EHR for Cancer Care Teams

Image
Oracle Launches AI-Powered Oncology EHR for Cancer Care Teams

Orlando, Fla. – September 24, 2026 -- Oracle unveiled Oracle Health Oncology EHR, a new ambulatory electronic health record system purpose-built for cancer care, combining oncology-specific workflows with AI-driven clinical intelligence at the Oracle Health and Life Sciences Summit.

Oracle targets fragmented oncology data with unified patient timelines

The platform is designed to consolidate cancer diagnoses, chemotherapy regimens, laboratory and imaging results, medications, referrals, and insurance requirements into a single chronological record spanning inpatient and outpatient settings. Oracle states that fragmented information currently forces clinicians to spend time reassembling patient context while patients repeatedly recount their medical history across care settings.

Werfen Wins FDA Clearance, CE Mark for Aptiva APS IgA Assay

Image
Werfen Wins FDA Clearance, CE Mark for Aptiva APS IgA Assay

San Diego – September 24, 2026 -- Werfen has secured U.S. FDA 510(k) clearance and a CE Mark under the EU's IVDR for its Aptiva Antiphospholipid Syndrome (APS) IgA Reagent, completing a three-isotype APS testing portfolio on its Aptiva platform.

Aptiva now covers all three APS antibody isotypes for global laboratories

The clearance means Aptiva offers IgA, IgG, and IgM testing for both anti-cardiolipin (aCL) and anti-beta 2 glycoprotein 1 (aβ2GP1) antibodies, giving laboratories a full antibody profile for antiphospholipid syndrome, an autoimmune disease linked to thrombotic events and pregnancy complications that is often difficult to diagnose due to overlapping clinical symptoms.

Theragen Data Shows 13-Hour Wear Threshold Predicts Spinal Fusion Recovery

Image
Theragen Data Shows 13-Hour Wear Threshold Predicts Spinal Fusion Recovery

Jacksonville, Florida – September 24, 2026 -- Theragen presented machine-learning findings at the Society for Minimally Invasive Spine Surgery (SMISS) 2026 Annual Forum showing that daily wear time of its ActaStim®-S bone growth stimulator predicts clinically meaningful pain improvement after spinal fusion surgery, with benefits plateauing around 13 hours of daily use.

Nearly 7,000 patients and 195,000 patient-days of data feed predictive model

The analysis drew on almost 7,000 patients and approximately 195,000 patient-day observations collected through ActaStim-S, a wearable electrical stimulation device paired with a digital health platform. A standardized device-to-electronic medical record pipeline achieved 99.2% data completeness across the dataset, according to Theragen.

Qualtrics Launches Healthcare XM, Names Dr. Thomas Lee to XM Institute

Image
Qualtrics Launches Healthcare XM, Names Dr. Thomas Lee to XM Institute

Provo, Utah – September 24, 2026 -- Qualtrics unveiled Healthcare XM, a new platform built on Press Ganey's proprietary data and what the company calls the world's largest human experiential dataset, aimed at helping health systems and health plans simulate care changes, predict patient behavior, and act on safety risks before they escalate.

Qualtrics builds Healthcare XM on Press Ganey data to close the industry's experience gap

The platform runs on the Qualtrics XM Data & AI Platform and combines decades of Press Ganey benchmarks, regulatory expertise, and predictive analytics. It covers five domains: patient experience across HCAHPS and CAHPS journeys, member experience including Medicare CAHPS and Stars ratings, workforce engagement and retention, safety and quality signals such as NDNQI and PSO data, and consumer and brand positioning.

Cardiol Expands Phase III Pericarditis Trial to 150 Patients

Image
Cardiol Expands Phase III Pericarditis Trial to 150 Patients

Toronto – September 24, 2026 -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) has hit its 110-patient enrollment target for the pivotal Phase III MAVERIC trial ahead of its end-of-September guidance, and will now expand recruitment to as many as 150 patients.

Blinded review shows fewer recurrences than expected in pericarditis trial

A blinded review of patients randomized 1:1 to CardiolRxTM or placebo found a lower-than-anticipated rate of pericarditis recurrence, according to Cardiol. The MAVERIC Steering Committee recommended the enrollment increase to capture enough clinical events for a statistically robust efficacy read.

President and CEO David Elsley said the company is not aware of any change in routine clinical practice that would explain the reduced recurrence rate, calling the finding encouraging.

DEXIS Launches Portfolio-Wide Upgrade Across Dental Imaging Ecosystem

Image
DEXIS Launches Portfolio-Wide Upgrade Across Dental Imaging Ecosystem

Quakertown, Pa. – September 24, 2026 -- DEXIS unveiled a coordinated set of upgrades spanning hardware, software, cloud and service offerings across its dental imaging ecosystem, unveiled during the company's ILLUMINATE virtual keynote.

NOMAD Pro 3 upgrades handheld X-ray hardware with improved image quality and durability

The new NOMAD Pro 3 builds on DEXIS' handheld X-ray system, adding enhanced image quality and durability while maintaining safety-first engineering standards. Separately, the ORTHOPANTOMOGRAPH OP 3D gains a Motion Correction feature that reduces the impact of patient movement on CBCT image clarity without requiring hardware changes.